Celcuity secured U.S. FDA approval for Revtorpyk (gedatolisib) in HR+/HER2− locally advanced or metastatic breast cancer for patients without a PIK3CA mutation after progression on or following at least one line of endocrine therapy. The approval covers an intravenous PAM pathway inhibitor used with fulvestrant, with or without palbociclib, marking Celcuity’s first U.S. commercial launch. The product’s launch timing also became a trading focus. Multiple reports tied investor scrutiny to the company’s delayed go-to-market expectations into late Q3 2026 despite the regulatory milestone, highlighting how commercialization execution can swing market perception even when clinical efficacy supports the label. Separately, Qiagen won CE-IVD certification for its QiaStat-Dx BCID GN Plus AMR Panel for bloodstream infection testing. The one-hour molecular assay detects 13 gram-negative pathogens and 18 AMR markers from positive blood cultures, expanding Qiagen’s BCID panel coverage on its PCR-based QiaStat-Dx platform. Together, the Celcuity approval and Qiagen’s certification show a two-track push in oncology and diagnostics—new targeted therapies reaching patients while faster, expanded syndromic testing aims to tighten antimicrobial stewardship and treatment decisions for severe infections.